291 related articles for article (PubMed ID: 34813863)
1. A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome.
van Hoogdalem MW; Wexelblatt SL; Akinbi HT; Vinks AA; Mizuno T
Pharmacol Ther; 2022 Jun; 234():108045. PubMed ID: 34813863
[TBL] [Abstract][Full Text] [Related]
2. Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches.
McPhail BT; Emoto C; Butler D; Fukuda T; Akinbi H; Vinks AA
J Clin Pharmacol; 2021 Jul; 61(7):857-870. PubMed ID: 33382111
[TBL] [Abstract][Full Text] [Related]
3. Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome.
van Hoogdalem MW; Johnson TN; McPhail BT; Kamatkar S; Wexelblatt SL; Ward LP; Christians U; Akinbi HT; Vinks AA; Mizuno T
Clin Pharmacol Ther; 2022 Feb; 111(2):496-508. PubMed ID: 34679189
[TBL] [Abstract][Full Text] [Related]
4. Neonatal opioid toxicity: opioid withdrawal (abstinence) syndrome with emphasis on pharmacogenomics and respiratory depression.
Baldo BA
Arch Toxicol; 2023 Oct; 97(10):2575-2585. PubMed ID: 37537419
[TBL] [Abstract][Full Text] [Related]
5. A review of the literature: How does prenatal opioid exposure impact placental health and fetal brain development?
Humphries A; Simcox K; Howell B
Dev Psychobiol; 2023 Apr; 65(3):e22378. PubMed ID: 36946682
[TBL] [Abstract][Full Text] [Related]
6. Placental DNA methylation profiles in opioid-exposed pregnancies and associations with the neonatal opioid withdrawal syndrome.
Radhakrishna U; Vishweswaraiah S; Uppala LV; Szymanska M; Macknis J; Kumar S; Saleem-Rasheed F; Aydas B; Forray A; Muvvala SB; Mishra NK; Guda C; Carey DJ; Metpally RP; Crist RC; Berrettini WH; Bahado-Singh RO
Genomics; 2021 May; 113(3):1127-1135. PubMed ID: 33711455
[TBL] [Abstract][Full Text] [Related]
7. Transplacental methadone exposure and risk of Neonatal Opioid Withdrawal Syndrome.
Bhatt-Mehta V; Jing X; Wang X; Zhu HJ
Pharmacotherapy; 2024 Jan; 44(1):22-27. PubMed ID: 37574548
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics.
van Hoogdalem MW; McPhail BT; Hahn D; Wexelblatt SL; Akinbi HT; Vinks AA; Mizuno T
Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):87-103. PubMed ID: 33049155
[TBL] [Abstract][Full Text] [Related]
9. Fetal gastric area ratio to predict severe neonatal opioid withdrawal syndrome.
Townsel C; Stone J; Debolt C; Hussain N; Campbell WA
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):7957-7961. PubMed ID: 34151686
[TBL] [Abstract][Full Text] [Related]
10. Severity of neonatal opioid withdrawal syndrome with prenatal exposure to serotonin reuptake inhibitors.
Bakhireva LN; Sparks A; Herman M; Hund L; Ashley M; Salisbury A
Pediatr Res; 2022 Mar; 91(4):867-873. PubMed ID: 34588611
[TBL] [Abstract][Full Text] [Related]
11. Maternal and iatrogenic neonatal opioid withdrawal syndrome: Differences and similarities in recognition, management, and consequences.
Isaac L; van den Hoogen NJ; Habib S; Trang T
J Neurosci Res; 2022 Jan; 100(1):373-395. PubMed ID: 33675100
[TBL] [Abstract][Full Text] [Related]
12. Maternal opioid use disorder: Placental transcriptome analysis for neonatal opioid withdrawal syndrome.
Radhakrishna U; Nath SK; Vishweswaraiah S; Uppala LV; Forray A; Muvvala SB; Mishra NK; Southekal S; Guda C; Govindamangalam H; Vargas D; Gardella WG; Crist RC; Berrettini WH; Metpally RP; Bahado-Singh RO
Genomics; 2021 Nov; 113(6):3610-3617. PubMed ID: 34352367
[TBL] [Abstract][Full Text] [Related]
13. Assessing the Impact of Prenatal Medication for Opioid Use Disorder on Discharge Home With Parents Among Infants With Neonatal Opioid Withdrawal Syndrome.
Singleton R; Rutz S; Day G; Hammes M; Wilson AS; Herrick M; Mazut C; Brunner L; Prince J; Desnoyers C; Shaw J; Hirschfeld M; Palis H; Slaunwhite A
J Addict Med; 2022 Nov-Dec 01; 16(6):e366-e373. PubMed ID: 35245916
[TBL] [Abstract][Full Text] [Related]
14. Predicting Maternal-Fetal Disposition of Fentanyl Following Intravenous and Epidural Administration Using Physiologically Based Pharmacokinetic Modeling.
Shum S; Shen DD; Isoherranen N
Drug Metab Dispos; 2021 Nov; 49(11):1003-1015. PubMed ID: 34407992
[TBL] [Abstract][Full Text] [Related]
15. The Influence of Mediators on the Relationship Between Antenatal Opioid Agonist Exposure and the Severity of Neonatal Opioid Withdrawal Syndrome.
Devlin LA; Hu Z; Ounpraseuth S; Simon AE; Annett RD; Das A; Fuller JF; Higgins RD; Merhar SL; Smith PB; Crawford MM; Cottrell LE; Czynski AJ; Newman S; Paul DA; Sánchez PJ; Semmens EO; Smith MC; Whalen BL; Snowden JN; Young LW;
Matern Child Health J; 2023 Jun; 27(6):1030-1042. PubMed ID: 36905529
[TBL] [Abstract][Full Text] [Related]
16. Newborn Cry Acoustics in the Assessment of Neonatal Opioid Withdrawal Syndrome Using Machine Learning.
Manigault AW; Sheinkopf SJ; Silverman HF; Lester BM
JAMA Netw Open; 2022 Oct; 5(10):e2238783. PubMed ID: 36301544
[TBL] [Abstract][Full Text] [Related]
17. Neonatal opioid withdrawal syndrome: a review of the science and a look toward the use of buprenorphine for affected infants.
Devlin LA; Young LW; Kraft WK; Wachman EM; Czynski A; Merhar SL; Winhusen T; Jones HE; Poindexter BB; Wakschlag LS; Salisbury AL; Matthews AG; Davis JM
J Perinatol; 2022 Mar; 42(3):300-306. PubMed ID: 34556799
[TBL] [Abstract][Full Text] [Related]
18. Prenatal methadone exposure disrupts behavioral development and alters motor neuron intrinsic properties and local circuitry.
Grecco GG; Mork BE; Huang JY; Metzger CE; Haggerty DL; Reeves KC; Gao Y; Hoffman H; Katner SN; Masters AR; Morris CW; Newell EA; Engleman EA; Baucum AJ; Kim J; Yamamoto BK; Allen MR; Wu YC; Lu HC; Sheets PL; Atwood BK
Elife; 2021 Mar; 10():. PubMed ID: 33724184
[TBL] [Abstract][Full Text] [Related]
19. The Time is NOW: Filling the Gaps in Treatment of Opioid-Exposed Infants: A Prospective, Pragmatic, Randomized Control Drug Trial.
Czynski AJ; Laptook AR
R I Med J (2013); 2021 Apr; 104(3):17-21. PubMed ID: 33789403
[TBL] [Abstract][Full Text] [Related]
20. Hospital Outcomes of Infants with Neonatal Opioid Withdrawal Syndrome at a Tertiary Care Hospital with High Rates of Concurrent Nonopioid (Polysubstance) Exposure.
Morris E; Bardsley T; Schulte K; Seidel J; Shakib JH; Buchi KF; Fung CM
Am J Perinatol; 2022 Mar; 39(4):387-393. PubMed ID: 32892326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
